I personally don't believe AZ is working on dep-docetaxel with SPL.
I think the game plan for SPL is to churn out a quick (haha) Phase 2, maybe 12-18 months for the indications they desire, and own all the data post Phase 2. I think at that juncture they will then choose to license dep-docetaxel for the Phase 3.
I would much prefer them to take it all the way to market themselves, but at this point in time, they simply don't have the resources to do so.
SPL Price at posting:
$1.04 Sentiment: Hold Disclosure: Held
